Circular RNA study for B-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a new way to treat B-cell blood cancers that have not responded to other treatments or have come back. It tests a therapy that targets cancer cells using RNA, which is a molecule that helps make proteins in your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a B-cell blood cancer that is relapsed or refractory (has come back or did not respond to treatment)
- You have tried at least 2 prior standard treatments
- You have a tumor sample available or can provide one from a biopsy
- You are generally well with an ECOG performance status of 0 or 1 (able to do most daily activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 trial tests an investigational treatment called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to previous therapies. The goal is to see if the drug is safe and effective.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new immunotherapy, RN1201, for people with certain blood cancers (like multiple myeloma, leukemia, or lymphoma) that have come back or not responded to standard treatments. It aims to see if this treatment can help when other options have stopped working.
Hear when a new Lymphoma, B-Cell Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.